for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Circassia Group PLC

CIRCI.L

Latest Trade

30.73GBp

Change

0.43(+1.40%)

Volume

36,353

Today's Range

30.30

 - 

31.50

52 Week Range

19.86

 - 

37.90

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
30.30
Open
30.30
Volume
36,353
3M AVG Volume
19.26
Today's High
31.50
Today's Low
30.30
52 Week High
37.90
52 Week Low
19.86
Shares Out (MIL)
418.19
Market Cap (MIL)
126.71
Forward P/E
-35.03
Dividend (Yield %)
--

Next Event

Half Year 2021 Circassia Group PLC Earnings Release

Latest Developments

More

Circassia Says Settlement Agreement Reached With Beyond Air

Circassia Group Plc Says 4 Months Trading Was Slightly Ahead Of Management Expectations

Circassia Group FY Revenue 23.9 Million Stg

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Circassia Group PLC

Circassia Group Plc, formerly Circassia Pharmaceuticals Plc, is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company is primarily focused on offering its commercialized asthma management products directly to specialist physicians in various markets. The Company’s NIOX products are used to improve asthma and offers a portfolio of asthma and chronic obstructive pulmonary disease product candidates. The Company’s commercialized chronic obstructive pulmonary disease (COPD) products are Tudorza and Duaklir in the United States. The Company’s pipeline products also include late-stage nitric oxide product LungFit PH, which is a ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air.

Industry

Biotechnology & Drugs

Contact Info

Northbrook House, Robert Robinson Avenue

OX4 4GA

United Kingdom

+44.1865.405560

http://www.circassia.com/

Executive Leadership

Ian Roy Johnson

Executive Chairman of the Board

Michael Roller

Chief Financial Officer, Executive Director

Jonathan Emms

Chief Operating Officer, Executive Director

Sarah Duncan

Company Secretary

Nicholas Mills

Non-Independent Non-Executive Director

Key Stats

Revenue (MM, GBP)

2018

0.0K

2019

0.1K

2020

0.0K

2021(E)

0.1K
EPS (GBp)

2018

-7.520

2019

-11.000

2020

-7.000

2021(E)

-0.865
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.30
Price To Book (MRQ)
1.67
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
2.22
LT Debt To Equity (MRQ)
1.11
Return on Investment (TTM)
-18.23
Return on Equity (TTM)
-15.32

Latest News

Latest News

BRIEF-Circassia Group In Equity Finance Facility With Two Major Institutional Shareholders

* CIRCASSIA GROUP PLC - ENTERED INTO AN EQUITY FINANCE FACILITY WITH TWO OF ITS MAJOR INSTITUTIONAL SHAREHOLDERS

Woodford discloses less than 5% stake in Circassia Pharmaceuticals: filing

British asset manager Woodford Investment Management Ltd disclosed a less than 5% stake in Circassia Pharmaceuticals Plc <CIRCI.L> as of Sept. 13, a filing showed on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up